Determination of a new gastric cancer mortality predictor based on body composition radiodensity variables.

Authors

Mariana Caleffi, Daniela M H Padilha, Vinicius Bassete, Gianni Liveraro, Pedro Henrique Alves, Maria Emilia Seren Takahashi, Leo Victor Kim, Maria Carolina Santos Mendes, Jun Takahashi, José Barreto Campello Carvalheira

Published in

Clinical nutrition ESPEN. Pages 103132. Mar 21, 2026. Epub Mar 21, 2026.

Abstract

Prognostic assessment in gastric cancer relies primarily on TNM staging, yet outcomes vary substantially among patients within the same stage. Computed tomography (CT)-derived body composition parameters, particularly adipose and muscle radiodensity, have emerged as independent prognostic factors. We aimed to evaluate a novel variable integrating visceral adipose tissue (VAT) and skeletal muscle (SM) radiodensity as a prognostic marker in gastric cancer.
In this retrospective study, 461 patients with gastric adenocarcinoma diagnosed between 2009 and 2018 at the University of Campinas Hospital (Brazil) were included. CT images at the L3 level were segmented to quantify VAT, subcutaneous adipose tissue, and SM. Median radiodensity values (Hounsfield units, HU) were extracted. Combinations of CT-derived variables were tested for prognostic value, and the difference between VAT and SM median radiodensity (VMD) was selected. Patients were stratified into tertiles, and survival analyses were performed using Kaplan-Meier and Cox regression models adjusted for clinicopathological covariates.
Higher VMD values were strongly associated with poorer overall survival (OS) and disease-free survival (DFS). Median OS was 13.8 months in the highest tertile versus 58.5 months in the lowest tertile (p < 0.001). In multivariable analysis, VMD remained independently associated with mortality (HR 1.60, 95% CI 1.14 - 2.24, p < 0.05). Associations were particularly pronounced among women.
VMD represents a simple and reproducible CT-derived biomarker that complements TNM staging and enhances prognostic precision in gastric cancer. Its clinical feasibility supports future multicenter validation and potential integration into routine risk assessment.

PMID:
41871807
Bibliographic data and abstract were imported from PubMed on 24 Mar 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.